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Ebola Virus VP35 Interaction with Dynein LC8 Regulates Viral RNA
Synthesis
Priya Luthra,a David S. Jordan,b Daisy W. Leung,b Gaya K. Amarasinghe,b Christopher F. Baslera
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USAa; Department of Pathology and Immunology, Washington University
School of Medicine, St. Louis, Missouri, USAb
Ebola virus VP35 inhibits alpha/beta interferon production and functions as a viral polymerase cofactor. Previously, the 8-kDa
cytoplasmic dynein light chain (LC8) was demonstrated to interact with VP35, but the functional consequences were unclear.
Here we demonstrate that the interaction is direct and of high affinity and that binding stabilizes the VP35 N-terminal oligomer-
ization domain and enhances viral RNA synthesis. Mutational analysis demonstrates that VP35 interaction is required for the
functional effects of LC8.
Ebola virus (EBOV) VP35 is a multifunctional protein criti-cal for both viral innate immune evasion and viral RNA
synthesis (1, 2). It contains an N-terminal oligomerization do-
main and a C-terminal double-stranded RNA (dsRNA) bind-
ing domain referred to as the interferon inhibitory domain
(IID) (3, 4). VP35 acts as an interferon antagonist, using both
dsRNA-binding-dependent and -independent mechanisms, to
block the RIG-I-like receptor signaling pathways (5–9). VP35
also participates with the viral large protein (L), the enzymatic
component of the RNA-dependent RNA polymerase (RDRP)
complex, VP30, and nucleoprotein (NP) in viral RNA synthesis
(10, 11). VP35 is critical in this role because it mediates the
interaction between L and the RNA template-associated NP (2,
12–14).
VP35 can interact with the highly conserved 8-kDa cytoplas-
mic dynein light-chain (LC8) protein (15). LC8 is a subunit of the
cytoplasmic dynein motor complex, which plays an important
role in the microtubule-associated intracellular retrograde trans-
port system (16, 17). It also can exist in a soluble form without
association with the dynein motor or microtubule (18). LC8 exists
as a dimer containing two identical grooves located at opposite
faces of the protein dimer interface (19). These grooves bind to
proteins containing consensus motifs of either (K/S)XTQT or G
(I/V)QVD (20). VP35 contains an SQTQT motif that is required
for LC8 interaction (15). However, LC8 binding was not required
for, nor did it inhibit, VP35 interferon (IFN) antagonist function
(15, 21). Therefore, the significance of the VP35-LC8 interaction
has remained undefined.
Here we characterized the interaction between LC8 and
EBOV VP35 and provide evidence that the interaction stabi-
lizes the VP35 N-terminal oligomerization domain to enhance
viral RNA synthesis. The VP35-LC8 interaction was first vali-
dated by coimmunoprecipitation (co-IP). Briefly, HEK293T
cells were transfected with plasmids expressing hemagglutinin
(HA)-tagged LC8 (500 ng) and either full-length FLAG-tagged
VP35 (1 g) (GenBank accession no. AF086833.2) or a VP35
truncation mutant (1 g) corresponding to the VP35 N-termi-
nal domain (FLAG-VP35-N, residues 1 to 218) or the IID
(FLAG-VP35-C, residues 219 to 340). Twenty-four hours post-
transfection, anti-FLAG immunoprecipitations were per-
formed. Both wild-type (WT) VP35 and VP35-N coprecipi-
tated with LC8, confirming that VP35 binds LC8 via its N
terminus (Fig. 1A). Mutation to alanine of T73 or Q74 within
the VP35 71-SQTQT-75 motif disrupted or reduced the inter-
action, consistent with results of prior studies (15) (Fig. 1B).
To further characterize the interaction, LC8 and VP35
from residues 50 to 150 (VP35 50 –150) were expressed in
BL21(DE3) Escherichia coli from a modified pET15b vector (No-
vagen) containing a maltose binding protein (MBP) fusion tag.
Cells were lysed using a cell disrupter (Avestin) and centrifuged at
47,000  g to remove debris. Proteins were purified to homoge-
neity using a series of chromatographic columns (GE Healthcare),
including affinity and ion-exchange columns, prior to a final gel
filtration step into buffer containing 10 mM HEPES, pH 7, 150
mM NaCl, and 2 mM tris(2-carboxyethyl)phosphine (TCEP)
(Fig. 1C). With a size exclusion chromatography (SEC) column
coupled with a Dawn Heleos II multiangle light-scattering (MALS)
detector (Wyatt Technologies), MBP-LC8 was demonstrated
to behave as a dimer, consistent with results in previous reports
(Fig. 1D, blue line) (22, 23), while the MBP-VP35 50 –150 be-
haved as a tetramer (Fig. 1D, black line). Together, MBP-LC8
and MBP-VP35 50 –150 form a 1:1 complex, such that two LC8
dimers bind to one VP35 50-150 tetramer (Fig. 1D, green line).
Isothermal titration calorimetry (ITC) measurements using a
VP-ITC microcalorimeter (Malvern) revealed that VP35 has a
high affinity for LC8 (equilibrium dissociation constant [KD] 
82.4  18 nM), while a Q74A single mutant and a Q72A Q74A
double mutant that alter the LC8 binding motif in VP35 50 –150
show substantially diminished binding to LC8 (KD  900  260
nM and 1,200 160 nM, respectively) (Fig. 1E, middle and right
panels).
We next assessed the stability of VP35 upon LC8 binding using
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FIG 1 LC8 interacts with EBOV VP35 protein. (A) The N terminus of VP35 is sufficient to interact with LC8. A co-IP experiment was performed with
FLAG-tagged WT VP35, VP35-N (containing amino acids [aa] 1 to 218), VP35-C (aa 219 to 340), and HA-tagged LC8 (HA-LC8). VP35 proteins were pulled
down by anti-FLAG antibody, and protein expression was detected by Western blotting (immunoblotting [IB]). WCE, whole-cell extracts. (B) VP35 mediates the
interaction with LC8 via an LC8 binding consensus motif (K/SXTQT). VP35 mutants (the T73A and Q74A mutants) were utilized in a co-IP experiment with
HA-tagged LC8. Protein expression was detected by Western blotting with anti-VP35 and anti-HA antibodies. (C) SDS-PAGE gel of MBP-VP35 50 –150 Q74A
(lane 1), MBP-VP35 50 –150 (lane 2), MBP-LC8 (lane 3), and MBP (lane 4) used in SEC-MALS and ITC experiments. (D) VP35 forms a 1:1 complex with LC8.
Elution profiles of MBP-LC8 (blue), MBP-VP35 50 –150 (black), MBP-VP35 50 –150/MBP-LC8 complex (green), and MBP (inset) from a Superdex 200 column
were obtained and analyzed by SEC-MALS. The theoretical monomeric molecular masses for MBP-VP35 50 –150 and MBP-LC8 are 55.2 and 54.4 kDa,
respectively. (E) ITC data for MBP-LC8 binding to MBP-WT VP35 50 –150 (left), mutant MBP-VP35 50 –150 Q74A (center), and mutant MBP-VP35 50 –150
Q72A Q74A (right). Representative raw data and binding isotherms are shown, and the reported values for KD and n are averages from at least two independent
experiments.
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proteins lacking the MBP fusion tag (Fig. 2A). We performed
circular dichroism (CD) wavelength scans, using a Chirascan CD
spectrometer (Applied Photophysics), and monitored the change
in molar ellipticity of each protein from 10 to 90°C on samples
containing 5 to 10 M VP35 50 –150 and the VP35 50 –150 Q72A
Q74A mutant (Fig. 2B). CD results show that VP35 50 –150 has a
high alpha-helical content that persists even at higher tempera-
tures (Fig. 2B). Next, we conducted comparative thermal stability
analysis between VP35 50 –150 and the VP35 50 –150 Q72A Q74A
mutant in the presence of equimolar LC8. Introduction of the
Q72A and Q74A mutations did not significantly affect the stability
of VP35 50 –150 (Fig. 2B and C). In contrast, addition of LC8 to
VP35 50 –150, but not to VP35 50 –150 Q72A Q74A, differentially
enhanced stability. This stability enhancement was predomi-
nantly due to LC8-VP35 50 –150 binding, as judged by the stability
of the mutant control (melting temperature [Tm]  70.8  1°C
for VP35 50 –150 versus 66.4  2°C for the VP35 50 –150 Q72A
Q74A mutant) (Fig. 2D).
Previously, it was shown that LC8 interaction does not affect
VP35 interferon antagonist function, and studies in which we
compared levels of inhibition of beta interferon (IFN-) pro-
moter activation by wild-type VP35 versus T73A or Q74A
VP35 confirmed this conclusion (reference 15 and data not
shown). However, the effect of LC8 on VP35 viral polymerase
cofactor function had not been addressed. We therefore uti-
lized an established EBOV minigenome assay where a model
EBOV RNA encoding Renilla luciferase is transcribed and repli-
cated by a viral RDRP complex that is reconstituted by transfec-
tion (8, 10). LC8 overexpression enhanced minigenome activity in
a dose-dependent manner, with the highest concentration of LC8
plasmid yielding a statistically significant increase. The stimula-
tion was more apparent when lower-than-optimal levels of WT
VP35 were used (Fig. 3A). Representative Western blots indicated
that VP35 expression levels were similar for each condition and
confirmed LC8 expression (Fig. 3A). When VP35 mutants T73A
and Q74A were tested, each exhibited reduced activity compared
to WT VP35, even when expression levels were accounted for (Fig.
3B; compare the 125-ng conditions for mutant VP35s to the 50-ng
conditions for WT VP35). Further, addition of LC8 did not en-
hance minigenome activity in the mutant VP35 samples (Fig. 3B),
suggesting that LC8 binding to VP35 is critical for the LC8-medi-
ated enhancement of minigenome activity.
We also examined the impact of LC8 on viral transcription
by using a minigenome plasmid that lacks the viral antigeno-
mic replication promoter region. This previously described
construct lacks replication activity and specifically serves as a
measure of viral mRNA synthesis (24). Overexpression of LC8
increased transcription in the presence of WT VP35 but not in
the presence of VP35 T73A or VP35 Q74A. Further, VP35 T73A
and VP35 Q74A exhibited reduced transcription (Fig. 4A
and B).
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FIG 2 LC8 binding enhances the stability of the N terminus of VP35. (A) SDS-PAGE gel of VP35 50 –150 (lane 1) and LC8 (lane 2) used in circular
dichroism (CD) experiments. Lane M, molecular mass markers. (B) CD wavelength scans for WT VP35 50 –150 (black lines) and the VP35 50 –150 Q72A
Q74A mutant (red lines) at the temperatures indicated. Mean residue ellipticity is in 103 degrees · cm2 · dmol1. (C) Thermal denaturation (Tm) of WT
VP35 50 –150 (black, left axis; Tm 63.8 0.1°C), the VP35 50 –150 Q72A Q74A mutant (red, right axis; Tm 63.8 1°C), and LC8 (inset, blue; Tm
66.3  2°C) monitored at 222 nm. (D) Thermal denaturation of the WT VP35 50 –150/LC8 complex (black, left axis; Tm  70.8  1°C) and the VP35
50 –150 Q72A Q74A/LC8 mutant complex (red, right axis; Tm 66.4 2°C) monitored at 222 nm. Reported Tms are averages of results from at least two
independent experiments.
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function. First, we demonstrate that the VP35 oligomerization
domain forms tetramers in the context of VP35 50 –150. There-
fore, full-length VP35 is also likely a tetramer. This is consistent
with the ability of paramyxovirus P proteins, which are func-
tionally analogous to filoviral VP35 proteins, to tetramerize
(25, 26). Second, we show that VP35 50 –150 is sufficient for
high-affinity interaction with LC8 in the absence of other viral
or cellular factors and that mutation of the LC8-interacting
motif 71-SQTQT-75 disrupts interaction, further confirming
specificity (Fig. 1 and 2). Third, these data provide the first
evidence that LC8 interaction modulates EBOV RNA synthesis.
The enhancing activity is specific to the RNA synthesis func-
tions of VP35, as we and others have not seen the effects of the
T73A or Q74A mutation on IFN antagonist function (data not
shown and reference 15). The N-terminal oligomerization
function has previously been implicated as facilitating both
filoviral RNA synthesis and IFN antagonism (4, 12, 27). That
the enhancement of RNA synthesis requires the interaction of
LC8 with VP35 is demonstrated by the inability of LC8 to stim-
ulate activity when the VP35 mutants were used in the minige-
nome assay. Overall, the data suggest that LC8-dependent sta-
bilization of the oligomerization domain at least in part
accounts for the enhanced activity. Given that the impact of
LC8 is more dramatic when VP35 levels are limiting, LC8 may
function primarily early in infection, when levels of replication
complex proteins are low, serving as a means to rapidly estab-
lish viral gene expression before effective antiviral responses
can be initiated.
LC8 interacts with a variety of viral proteins to facilitate
movement of viral components (19, 20, 28–31). The rabies
virus P protein, which serves as a rabies virus polymerase co-
factor, also interacts with LC8 (32, 33). LC8-P protein interac-
tion was not needed for dynein-mediated viral transport but
was required for optimal rabies viral polymerase activity (33).
The molecular basis for enhanced rabies virus polymerase ac-
tivity was not defined, but our data suggest that LC8 stabilizes
the P protein oligomer. It will therefore be of interest to deter-
mine to what extent other negative-strand RNA viruses, in-
cluding other filoviruses, use a similar strategy to enhance their
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FIG 3 LC8 enhances EBOV RNA synthesis in a dose-dependent manner. (A) Increasing amounts of HA-tagged LC8 plasmid (50, 500 ng) were cotransfected
with the plasmids required to reconstitute the EBOV RNA polymerase complex (L, NP, VP35, VP30) along with a plasmid encoding the Renilla luciferase
minigenome RNA and a firefly luciferase expression plasmid, which served as a control for transfection efficiency. Relative activity was determined by normal-
izingRenilla luciferase activity to firefly luciferase activity. The error bars indicate standard deviations from three independent replicates. *,P 0.04; **,P 0.03,
as determined by Student’s t test. The Western blot shows expression of -tubulin, VP35, and LC8 (anti-HA antibody). (B) A minigenome experiment similar
to that described for panel A was performed except that WT VP35 or the indicated VP35 mutants were used, and the LC8 plasmid amount was kept constant at
500 ng. The error bars indicate standard deviations from three independent replicates. The Western blot shows the expression of VP35, LC8, and -tubulin,
detected with anti-VP35, anti-HA, and anti--tubulin antibodies, respectively. *, P 0.01; **, P 0.006, as determined by Student’s t test.
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FIG 4 LC8 expression enhances EBOV transcription. (A) A minigenome assay was performed as described for Fig. 2A, except that a replication-deficient
minigenome construct was used. *, P 0.01; **, P 0.0045, as determined by Student’s t test. (B) A minigenome experiment similar to that described for panel
A was performed except that WT VP35 or the indicated VP35 mutants were included and the LC8 plasmid amount was kept constant at 500 ng. The error bars
indicate standard deviations from three independent replicates. The Western blot shows the expression of VP35 and LC8, detected with anti-VP35 and anti-HA
antibodies, respectively. *, P 0.007; **, P 0.002, as determined by Student’s t test.
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